Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

New world origin of canine distemper: Interdisciplinary insights.

Uhl EW, Kelderhouse C, Buikstra J, Blick JP, Bolon B, Hogan RJ.

Int J Paleopathol. 2019 Mar;24:266-278. doi: 10.1016/j.ijpp.2018.12.007. Epub 2019 Feb 8. Review.

2.

Generation of H7N9-specific human polyclonal antibodies from a transchromosomic goat (caprine) system.

Wu H, Fan Z, Brandsrud M, Meng Q, Bobbitt M, Regouski M, Stott R, Sweat A, Crabtree J, Hogan RJ, Tripp RA, Wang Z, Polejaeva IA, Sullivan EJ.

Sci Rep. 2019 Jan 23;9(1):366. doi: 10.1038/s41598-018-36961-5.

3.

Antibodies Are Major Drivers of Protection against Lethal Aerosol Infection with Highly Pathogenic Burkholderia spp.

Hogan RJ, Lafontaine ER.

mSphere. 2019 Jan 2;4(1). pii: e00674-18. doi: 10.1128/mSphere.00674-18.

4.

Use of Immunohistochemistry to Demonstrate In Vivo Expression of the Burkholderia mallei Virulence Factor BpaB During Experimental Glanders.

Zimmerman SM, Long ME, Dyke JS, Jelesijevic TP, Michel F, Lafontaine ER, Hogan RJ.

Vet Pathol. 2018 Mar;55(2):258-267. doi: 10.1177/0300985817736113. Epub 2017 Nov 16.

PMID:
29145795
5.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

6.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

7.

Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.

Zimmerman SM, Dyke JS, Jelesijevic TP, Michel F, Lafontaine ER, Hogan RJ.

Infect Immun. 2017 Jul 19;85(8). pii: e00102-17. doi: 10.1128/IAI.00102-17. Print 2017 Aug.

8.

Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches.

Aschenbroich SA, Lafontaine ER, Hogan RJ.

Expert Rev Vaccines. 2016 Sep;15(9):1163-81. doi: 10.1586/14760584.2016.1170598. Epub 2016 Apr 20. Review.

PMID:
27010618
9.

Type II integral membrane protein, TM of J paramyxovirus promotes cell-to-cell fusion.

Li Z, Hung C, Paterson RG, Michel F, Fuentes S, Place R, Lin Y, Hogan RJ, Lamb RA, He B.

Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12504-9. doi: 10.1073/pnas.1509476112. Epub 2015 Sep 21.

10.

The Autotransporter BpaB Contributes to the Virulence of Burkholderia mallei in an Aerosol Model of Infection.

Zimmerman SM, Michel F, Hogan RJ, Lafontaine ER.

PLoS One. 2015 May 20;10(5):e0126437. doi: 10.1371/journal.pone.0126437. eCollection 2015.

11.

Use of the common marmoset to study Burkholderia mallei infection.

Jelesijevic T, Zimmerman SM, Harvey SB, Mead DG, Shaffer TL, Estes DM, Michel F, Quinn FD, Hogan RJ, Lafontaine ER.

PLoS One. 2015 Apr 10;10(4):e0124181. doi: 10.1371/journal.pone.0124181. eCollection 2015.

12.

Focus on Ebola virus research.

Dowling WE, Hogan RJ.

Viral Immunol. 2015 Feb;28(1):1-2. doi: 10.1089/vim.2015.1501. No abstract available.

13.

In ovo and in vitro susceptibility of American alligators (Alligator mississippiensis) to avian influenza virus infection.

Temple BL, Finger JW Jr, Jones CA, Gabbard JD, Jelesijevic T, Uhl EW, Hogan RJ, Glenn TC, Tompkins SM.

J Wildl Dis. 2015 Jan;51(1):187-98. doi: 10.7589/2013-12-321.

PMID:
25380354
14.

Fatal Canid Herpesvirus 1 Respiratory Infections in 4 Clinically Healthy Adult Dogs.

Kumar S, Driskell EA, Cooley AJ, Jia K, Blackmon S, Wan XF, Uhl EW, Saliki JT, Sanchez S, Krimer PM, Hogan RJ.

Vet Pathol. 2015 Jul;52(4):681-7. doi: 10.1177/0300985814556190. Epub 2014 Oct 30.

PMID:
25358536
15.

Characterization of an autotransporter adhesin protein shared by Burkholderia mallei and Burkholderia pseudomallei.

Lafontaine ER, Balder R, Michel F, Hogan RJ.

BMC Microbiol. 2014 Apr 14;14:92. doi: 10.1186/1471-2180-14-92.

16.

Use of a safe, reproducible, and rapid aerosol delivery method to study infection by Burkholderia pseudomallei and Burkholderia mallei in mice.

Lafontaine ER, Zimmerman SM, Shaffer TL, Michel F, Gao X, Hogan RJ.

PLoS One. 2013 Oct 2;8(10):e76804. doi: 10.1371/journal.pone.0076804. eCollection 2013.

17.

Use of the Chinchilla model to evaluate the vaccinogenic potential of the Moraxella catarrhalis filamentous hemagglutinin-like proteins MhaB1 and MhaB2.

Shaffer TL, Balder R, Buskirk SW, Hogan RJ, Lafontaine ER.

PLoS One. 2013 Jul 2;8(7):e67881. doi: 10.1371/journal.pone.0067881. Print 2013.

18.

Infection of mice, ferrets, and rhesus macaques with a clinical mumps virus isolate.

Xu P, Huang Z, Gao X, Michel FJ, Hirsch G, Hogan RJ, Sakamoto K, Ho W, Wu J, He B.

J Virol. 2013 Jul;87(14):8158-68. doi: 10.1128/JVI.01028-13. Epub 2013 May 15.

19.

Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge.

Li Z, Mooney AJ, Gabbard JD, Gao X, Xu P, Place RJ, Hogan RJ, Tompkins SM, He B.

J Virol. 2013 Jan;87(1):354-62. doi: 10.1128/JVI.02321-12. Epub 2012 Oct 17.

20.

Peripheral arterial desaturation is further exacerbated by exercise in adolescents with acute mountain sickness.

Major SA, Hogan RJ, Yeates E, Imray CH.

Wilderness Environ Med. 2012 Mar;23(1):15-23. doi: 10.1016/j.wem.2011.12.008.

PMID:
22441084
21.

Glycoprotein J of infectious laryngotracheitis virus is required for efficient egress of infectious virions from cells.

Mundt A, Mundt E, Hogan RJ, García M.

J Gen Virol. 2011 Nov;92(Pt 11):2586-9. doi: 10.1099/vir.0.031443-0. Epub 2011 Jul 13.

PMID:
21752963
22.

Programming the magnitude and persistence of antibody responses with innate immunity.

Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, García-Sastre A, Compans R, Pulendran B.

Nature. 2011 Feb 24;470(7335):543-7. doi: 10.1038/nature09737.

23.

Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy.

Weart CW, Hogan RJ.

Expert Opin Pharmacother. 2011 Jan;12(1):99-117. doi: 10.1517/14656566.2010.516747. Epub 2010 Nov 26. Review.

PMID:
21108580
24.

Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination.

Wen Y, Wang H, Wu H, Yang F, Tripp RA, Hogan RJ, Fu ZF.

J Virol. 2011 Feb;85(4):1634-44. doi: 10.1128/JVI.01552-10. Epub 2010 Nov 24.

25.

Identification of Burkholderia mallei and Burkholderia pseudomallei adhesins for human respiratory epithelial cells.

Balder R, Lipski S, Lazarus JJ, Grose W, Wooten RM, Hogan RJ, Woods DE, Lafontaine ER.

BMC Microbiol. 2010 Sep 28;10:250. doi: 10.1186/1471-2180-10-250.

26.

Rats susceptible to virus-induced asthma have a persistent virus-induced change in the predominant pulmonary form of the NF-κB inhibitor IκBα.

Uhl EW, Clarke TJ, Lester C, Hogan RJ.

Vet Pathol. 2010 Nov;47(6):1021-7. doi: 10.1177/0300985810382521. Epub 2010 Sep 3.

PMID:
20817891
27.

Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles.

Song JM, Hossain J, Yoo DG, Lipatov AS, Davis CT, Quan FS, Chen LM, Hogan RJ, Donis RO, Compans RW, Kang SM.

Virology. 2010 Sep 15;405(1):165-75. doi: 10.1016/j.virol.2010.05.034. Epub 2010 Jun 26.

28.
29.

Characterization of conformation-specific monoclonal antibodies against rabies virus nucleoprotein.

Jiang Y, Luo Y, Michel F, Hogan RJ, He Y, Fu ZF.

Arch Virol. 2010 Aug;155(8):1187-92. doi: 10.1007/s00705-010-0709-x. Epub 2010 Jun 4. Review.

30.

Immunogenicity of avian H5N1 influenza virus recombinant vaccines in cats.

Uhl EW, Harvey SB, Michel F, Perozo Y, Gabbard J, Tompkins SM, Hogan RJ.

Viral Immunol. 2010 Apr;23(2):221-6. doi: 10.1089/vim.2009.0058.

PMID:
20374002
31.

Differential expression of nuclear factor-kappaB mediates increased pulmonary expression of tumor necrosis factor-alpha and virus-induced asthma.

Uhl EW, Clarke TJ, Hogan RJ.

Viral Immunol. 2009 Apr;22(2):79-89. doi: 10.1089/vim.2008.0083.

PMID:
19326995
32.

Comparison of balloon-carried atmospheric motion sensors with Doppler lidar turbulence measurements.

Harrison RG, Heath AM, Hogan RJ, Rogers GW.

Rev Sci Instrum. 2009 Feb;80(2):026108. doi: 10.1063/1.3086432.

PMID:
19256683
33.

Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.

Subramanian GM, Moore PA, Gowen BB, Olsen AL, Barnard DL, Paragas J, Hogan RJ, Sidwell RW.

Chemotherapy. 2008;54(3):176-80. doi: 10.1159/000140361. Epub 2008 Jun 18.

PMID:
18560223
34.

Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.

Raviv Y, Blumenthal R, Tompkins SM, Humberd J, Hogan RJ, Viard M.

J Virol. 2008 May;82(9):4612-9. doi: 10.1128/JVI.02233-07. Epub 2008 Feb 27.

35.

A three-dimensional magnetometer for motion sensing of a balloon-carried atmospheric measurement package.

Harrison RG, Rogers GW, Hogan RJ.

Rev Sci Instrum. 2007 Dec;78(12):124501. doi: 10.1063/1.2815349.

PMID:
18163738
36.

Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques.

Kobinger GP, Figueredo JM, Rowe T, Zhi Y, Gao G, Sanmiguel JC, Bell P, Wivel NA, Zitzow LA, Flieder DB, Hogan RJ, Wilson JM.

Vaccine. 2007 Jul 9;25(28):5220-31. Epub 2007 May 7.

PMID:
17559989
37.

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.

Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL.

Emerg Infect Dis. 2007 Mar;13(3):426-35.

38.

Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.

Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C.

J Virol. 2007 Feb;81(4):1821-37. Epub 2006 Dec 6.

39.

Are nonhuman primates good models for SARS?

Hogan RJ.

PLoS Med. 2006 Sep;3(9):e411; author reply e415. No abstract available.

40.

Fast approximate calculation of multiply scattered lidar returns.

Hogan RJ.

Appl Opt. 2006 Aug 10;45(23):5984-92.

PMID:
16926887
41.

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.

See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, Graham FL, Prevec L, Mahony JB, Sharon C, Auperin TC, Rini JM, Tingle AJ, Scheifele DW, Skowronski DM, Patrick DM, Voss TG, Babiuk LA, Gauldie J, Roper RL, Brunham RC, Finlay BB.

J Gen Virol. 2006 Mar;87(Pt 3):641-50.

PMID:
16476986
42.

Differential expression of chlamydial signal transduction genes in normal and interferon gamma-induced persistent Chlamydophila pneumoniae infections.

Polkinghorne A, Hogan RJ, Vaughan L, Summersgill JT, Timms P.

Microbes Infect. 2006 Jan;8(1):61-72. Epub 2005 Jul 22.

PMID:
16269262
43.

Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.

Olinger GG, Bailey MA, Dye JM, Bakken R, Kuehne A, Kondig J, Wilson J, Hogan RJ, Hart MK.

J Virol. 2005 Nov;79(22):14189-96.

44.

Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1.

Hogan RJ, Gao G, Rowe T, Bell P, Flieder D, Paragas J, Kobinger GP, Wivel NA, Crystal RG, Boyer J, Feldmann H, Voss TG, Wilson JM.

J Virol. 2004 Oct;78(20):11416-21.

45.

Macaque model for severe acute respiratory syndrome.

Rowe T, Gao G, Hogan RJ, Crystal RG, Voss TG, Grant RL, Bell P, Kobinger GP, Wivel NA, Wilson JM.

J Virol. 2004 Oct;78(20):11401-4.

46.

An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.

Zhou T, Wang H, Luo D, Rowe T, Wang Z, Hogan RJ, Qiu S, Bunzel RJ, Huang G, Mishra V, Voss TG, Kimberly R, Luo M.

J Virol. 2004 Jul;78(13):7217-26.

47.

Chlamydial persistence: beyond the biphasic paradigm.

Hogan RJ, Mathews SA, Mukhopadhyay S, Summersgill JT, Timms P.

Infect Immun. 2004 Apr;72(4):1843-55. Review. No abstract available.

48.

Orthodontic and cosmetic dental masking of avulsed maxillary central incisors.

Shaw BM, Hogan RJ.

N Y State Dent J. 2003 Dec;69(10):22-3.

PMID:
14974188
49.

Renewal of peripheral CD8+ memory T cells during secondary viral infection of antibody-sufficient mice.

Cauley LS, Cookenham T, Hogan RJ, Crowe SR, Woodland DL.

J Immunol. 2003 Jun 1;170(11):5597-606.

50.

Differential expression of genes encoding membrane proteins between acute and continuous Chlamydia pneumoniae infections.

Hogan RJ, Mathews SA, Kutlin A, Hammerschlag MR, Timms P.

Microb Pathog. 2003 Jan;34(1):11-6.

PMID:
12620380

Supplemental Content

Loading ...
Support Center